Assess whether to resubmit, meet, or pause the program from biosimilar

SITUATION A literature paper the 505(b)(2) package leans on getting retracted put biosimilar analytical similarity report in front of RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study. This Pharma & Life Sciences / FDA Response and Labeling close is to resubmit, meet, or from biosimilar analytical similarity report, and the live options are To resubmit, meet,, Pause the program.

DECISION RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study must choose To resubmit, meet, / Pause the program using biosimilar analytical similarity report after a literature paper the 505(b)(2) package leans on getting retracted.

HYPOTHESES TO TEST 1. Authorize To resubmit, meet, now; biosimilar analytical similarity report already has the discriminator after a literature paper the 505(b)(2) package leans on getting retracted. 2. Keep Pause the program in force until biosimilar analytical similarity report is completed after a literature paper the 505(b)(2) package leans on getting retracted for RWE evidence-strategy director. 3. Treat biosimilar analytical similarity report as To resubmit, meet, because both readings appear after a literature paper the 505(b)(2) package leans on getting retracted. 4. Refuse a Pharma & Life Sciences close: RWE evidence-strategy director does not have the decision to resubmit, meet, or turns on in biosimilar analytical similarity report.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 2. Check whether biosimilar analytical similarity report supports the labeled claim RWE evidence-strategy director would keep. 3. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read biosimilar analytical similarity report against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move to resubmit, meet, or for RWE evidence-strategy director.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / FDA Response and Labeling packet (biosimilar analytical similarity report after a literature paper the 505(b)(2) package leans on getting retracted). The follow-on FDA Response and Labeling action is what RWE evidence-strategy director does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in biosimilar analytical similarity report, then the action for RWE evidence-strategy director - Hypothesis scorecard against biosimilar analytical similarity report: supported / rejected / untestable - Missing page in biosimilar analytical similarity report after a literature paper the 505(b)(2) package leans on getting retracted, if any - Regulatory or exam hook FDA Response and Labeling would cite